Epidemiological studies support the hypothesis that genetic factors modulate the risk for diabetic nephropathy (DN). Aldose reductase (ALDR1), the rate-limiting enzyme in the polyol pathway, is a potential candidate gene. The present study explores the hypothesis that polymorphisms of the (A-C)n dinucleotide repeat sequence, located 2.1 kb upstream of the transcription start site, modulate ALDR1 gene expression and the risk for DN.
disease [odds ratio (OR), 5.25; 95% confidence interval, 1.71-17.98; P ϭ 0.005]. ALDR1 mRNA levels were higher in patients with DN (group III; 0.113 Ϯ 0.050) than in group I (0.068 Ϯ 0.025), group II (0.042 Ϯ 0.020), or group IV (0.015 Ϯ 0.011; P Ͻ 0.01). Among diabetics, ALDR1 mRNA levels were higher in ZϪ2 homozygotes (0.098 Ϯ 0.06) and ZϪ2 heterozygotes (0.080 Ϯ 0.04) than in patients with no ZϪ2 allele (0.043 Ϯ 0.02; P Ͻ 0.05). In contrast, among nondiabetics, ALDR1 mRNA levels in ZϪ2 homozygotes (0.034 Ϯ 0.04) and ZϪ2 heterozygotes (0.038 Ϯ 0.03) were similar to levels in patients without a ZϪ2 allele (0.047 Ϯ 0.03; P ϭ NS).
At HSR we identified eight alleles ranging from ZϪ12 to Zϩ2. The prevalence of the ZϪ2 allele was higher in group III than in group II. In group III, 43% of the patients were homozygous for ZϪ2, and 81% had one copy or more of the ZϪ2 allele. In contrast, in group II, 4% were homozygous for ZϪ2, and 36% had one copy or more of the ZϪ2 allele. IDDM patients homozygous for ZϪ2 had an increased risk for DN compared with those lacking the ZϪ2 allele (OR, 18; 95% confidence interval, 2-159). IDDM patients who had one copy or more of ZϪ2 had increased risk (OR, 7.5; 95% confidence interval, 1.9 -29.4) for DN compared with those without the ZϪ2 allele.
These results support our hypothesis that environmental-genetic interactions modulate the risk for DN. Specifically, the ZϪ2 allele, in the presence of diabetes and/or hyperglycemia, is associated with increased ALDR1 expression. This interaction may explain the observed association between the ZϪ2 allele and DN. (J Clin Endocrinol Metab 83: 2886 -2891, 1998) S EVERAL lines of evidence support the hypothesis that genetic factors modulate the risk for diabetic nephropathy (DN) (1) (2) (3) . Environmental factors may interact with genetic determinants to regulate gene expression and the risk for DN. Epidemiological studies have shown that the prevalence of DN varies significantly in different ethnic groups (4 -6) . A genome-wide scan performed in Pima Indians demonstrated positive linkage between DN and several genetic loci (7) .
One candidate gene that may modulate the risk for DN is aldose reductase (ALDR1). ALDR1, the rate-limiting enzyme in the polyol pathway, catalyzes the NADPH-dependent reduction of sugar aldehydes to their corresponding sugar polyols. ALDR1 is expressed in tissues that are targets for the chronic complications of diabetes (8 -11) , including the renal cortex (12) (13) (14) (15) . Increased activity of the polyol pathway has been implicated in the pathogenesis of DN in humans and animals (16 -18) . Sibling pair analyses in Pima Indians has shown linkage of DN with the ALDR1 microsatellite locus of chromosome 7 (7). Therefore, a gene(s) located at or near the ALDR1 locus may play a role in determining susceptibility to DN.
Studies of ALDR1 messenger ribonucleic acid (mRNA) and activity levels also support a role for the polyol pathway in the pathogenesis of DN. We previously demonstrated that expression of renal cortical ALDR1 mRNA is regulated (12) . Other laboratories have demonstrated reversal of diabetesrelated renal microvascular complications by administration of ALDR1 inhibitors (19 -21) . Conversely, increased ALDR1 levels lead to an accelerated rate of microvascular complications in transgenic mice overexpressing the ALDR1 gene (22, 23) . Significant heterogeneity in ALDR1 expression has been observed in humans. Elevated ALDR1 levels have been reported in neutrophils (24) , erythrocytes (25, 26) , and peripheral blood mononuclear cells (PBMC) (27) isolated from patients with diabetic complications. We recently reported that ALDR1 mRNA levels in PBMC were 3-fold higher in insulin-dependent diabetes mellitus (IDDM) patients with DN than in those without DN (28) . In contrast, ALDR1 mRNA levels were not elevated in nondiabetics with renal disease.
Ko et al. (29) (30) .
The present study explores the hypothesis that the ALDR1 ZϪ2 microsatellite is linked to increased ALDR1 expression and DN. We characterized the relationship between ALDR1 genotype and ALDR1 mRNA in volunteers of two different institutions, the University of New Mexico Health Science Center (UNMHSC) in Albuquerque, NM, and the Istituto Scientifico H San Raffaele (HSR) in Milan, Italy.
Subjects and Methods

Human subjects
The protocol was approved by the human subjects research review committees at the UNMHSC and HSR. Informed written consent was obtained from all volunteers. We studied 175 individuals (108 from UNMHSC and 67 from HSR). Sixty of the volunteers from UNMHSC participated in a study previously reported in this journal (28) . For all subjects we recorded a medical history and results of a physical examination, serum chemistry profile, hemoglobin A 1c (HbA 1c ), and dipstick, and for all diabetic patients, a dilated retinal exam was conducted by blinded ophthalmologists with expertise in diabetic retinopathy.
UNMHSC. Volunteers were recruited from an advertisement placed at the out-patient internal medicine and nephrology clinics. We studied four groups of volunteers: group I, normal volunteers (n ϭ 33); group II, IDDM without DN (n ϭ 27); group III, IDDM with DN (n ϭ 31); and group IV, nondiabetics with renal disease (n ϭ 17). Three random, daytime, spot urine samples were obtained from each volunteer for determination of the urinary albumin/creatinine ratio (UACR). Proteinuria was categorized using the mean UACR as normal (Ͻ0.03), subclinical (Ն0.03 to Ͻ0.3), or clinical (Ն0.3). HbA 1c , serum and urinary creatinine, and urinary albumin were measured as previously described (28) . The diagnosis of diabetes was confirmed by measuring plasma glucose, C peptide (31) , and serum free insulin (32) concentrations, fasting and 2 h after Sustacal (Mead Johnson, Evansville, IN) challenge (33) .
HSR.
We studied three groups of volunteers recruited from the diabetes clinics: group I, normal volunteers (n ϭ 21); group II, IDDM without DN (n ϭ 25); and group III, IDDM with DN (n ϭ 21). Group III included patients who had received a kidney (n ϭ 4) or a combined kidney and pancreas (n ϭ 12) transplant, patients with microalbuminuria (n ϭ 4), and patients with clinical proteinuria (n ϭ 1). A timed overnight urine collection was obtained from each volunteer for determination of the urinary albumin excretion rate. Urinary albumin excretion was categorized as normal (Ͻ20 g/min), microalbuminuria (20 -200 g/min), or clinical (Ͼ200 g/min). HbA 1c , serum and urinary creatinine, and urinary albumin were measured as previously described (28) . IDDM was diagnosed by clinical criteria, i.e. all IDDM patients were diagnosed before 30 yr of age, were ketosis prone, and were insulin dependent (34) .
Structural and functional polymorphism of the ALDR1 gene
PBMC were isolated from 20 mL uncoagulated blood using a standard method of Ficoll-Hypaque density gradient centrifugation. RNA and DNA were isolated from the same sample of PBMC using RNA-DNA STAT 60 kit (Tel-Test B, Friendswood, TX).
Automated fluorescent gene scanning detection and analysis of PCR product containing the (A-C)n repeat sequence
The sense primer (5Ј-GAATCTTAACATGCTCTGAACC-3Ј as AR1) end labeled at the 5Ј-end with the fluorescent dye ROX (red fluorescent, Genosys Biotechnologies, The Woodlands, TX) and the antisense primer (5Ј-GCCCAGCCCTATACCTAGT-3Ј as AR2) flanking the 138-bp region were used in PCR amplification of the sequence containing the (A-C)n repeat. Thirty cycles of PCR amplification consisted of denaturation for 1 min at 94 C and annealing-extension for a total of 1 min at 61 C. The PCR product was combined with an aliquot of the internal lane standard labeled with fluorescent dye TAMRA (yellow fluorescent; Perkin-Elmer, Norwalk, CT). The mixture was then resolved by electrophoresis on a denaturing gel (6% urea-PAGE) using ABI 373 DNA sequencer (PerkinElmer). The internal lane standard was used to create a calibration curve of peak arrival time, which, in turn, was used to calculate the length of unknown PCR product automatically by ABI GENESCAN 672 software (Perkin-Elmer).
Automated DNA sequencing of PCR products containing the (A-C)n repeat sequence
All PCR products were sequence analyzed using the sense (AR1) and anti-sense (AR2) primers, as described above, with the same cycling conditions. The amplified PCR products were purified using Qiaquick spin column (Qiagen, Chatsworth, CA) to remove the primer contamination. A second sense primer (5Ј-AGTAATCTCCCACTATGGGAA-3Ј as AR3) internal to the AR1 sense primer was used for extension reaction during the cycle sequencing amplification. PCR sequence cycling and purification of the extended product were performed as recommended by the manufacturer (Perkin-Elmer). The cycle sequencing products were electrophoresed on 6% urea-PAGE denaturing gel to confirm the (A-C)n repeat sequence of the PCR products.
Ribonuclease protection assay for measuring ALDR1 mRNA in PBMC
This method was performed as previously described (28) .
Statistical analysis
All statistical analyses were performed using SAS version 11.0 (Cary, NC) and LogXact (Cytel Software Corp., Cambridge, MA). Descriptive statistics for each group were computed for the following variables: age, blood pressure, UACR, serum creatinine, HgbA 1c , and ALDR1 mRNA. Data were tested for normality. Normally distributed data were presented as the mean and sd. Data that were not normally distributed were log transformed and tested again for normality. To test for differences between groups, we used ANOVA when the raw or transformed data were normally distributed. For data that were not normally distributed, we used the nonparametric Kruskal-Wallis procedure. If significant differences between groups were noted, we used multiple range tests (Newman-Keuls), as appropriate, to locate the differences. A three-way ANOVA for unbalanced design was used to examine the effects of diabetes, kidney disease, and specific ALDR1 polymorphisms on ALDR1 gene expression. Differences in the distributions of specific alleles among the four study groups were evaluated using either 2 or Fisher's exact test. Exact logistic regression models were used to assess the association between specific alleles and kidney disease, adjusting for diabetes.
Results
Clinical characteristics
UNMHSC. We studied 108 volunteers (48 women and 60 men; Caucasians, n ϭ 65; Hispanics, n ϭ 35; others, n ϭ 8). The distributions of gender and ethnicity were similar (P ϭ NS) in each group. The clinical characteristics of the study participants are shown in Table 1A . The mean age was similar in the 4 groups (P ϭ NS). The 2 diabetic groups were similar with respect to age (P ϭ NS), duration of diabetes (P ϭ NS), and glycemic control (P ϭ NS). Mean values for UACR and serum creatinine, respectively, were similar in diabetics (group III) and nondiabetics (group IV) with kidney disease. The types of renal disease represented in group IV included hypertensive nephrosclerosis (n ϭ 3), autosomal dominant polycystic kidney disease (n ϭ 3), glomerulonephritis (n ϭ 5), membranous nephropathy (n ϭ 2), Wegner's granulomatosis (n ϭ 1), and end-stage renal disease of unknown etiology (n ϭ 3).
HSR.
The clinical characteristics of the study population (n ϭ 67; all Caucasians) are shown in Table 1B . In IDDM patients without DN (group II), the mean duration of diabetes was 25.4 Ϯ 7.4 yr, exceeding 20 yr in all but 1 patient. The relatively low serum creatinine level observed in the group with DN (group III) reflects the fact that 16 patients had functioning renal grafts.
ALDR-1 genotypes UNMHSC
We identified 10 alleles ranging from ZϪ10 to Zϩ8 (Tables  2A and 3A ). There were no significant correlations between different alleles of the (A-C)n repeat and the age, sex, and ethnicity of the study participants. The presence of the ZϪ2 allele was increased in diabetics (groups II and III combined) compared with that in nondiabetics (groups I and IV combined; P Ͻ 0.001). Among diabetics, 60% of group III and 22% of group II were homozygous for ZϪ2. Moreover, 90% and 67% of groups III and II, respectively, had 1 copy or more of ZϪ2. In contrast, among nondiabetics, 19% of group IV and 3% of group I were homozygous for ZϪ2, and 69% and 33%, respectively, had 1 copy or more of ZϪ2. It is possible that some of the patients in group II with IDDM of less than 10-yr duration may develop DN. Therefore, we conducted a posthoc analysis to compare the frequency of the ZϪ2 allele in those members of group II who had IDDM of more than 10-yr duration with that in those with DN (group III). The frequency of the ZϪ2 allele was higher in group III than in group II (P Ͻ 0.05). Among diabetics, homozygosity for the ZϪ2 allele was associated with renal disease [odds ratio (OR), 5.25; 95% confidence interval, 1.71-17.98; P ϭ 0.005). Among nondiabetics, the prevalence of ZϪ2 homozygosity tended to be higher in patients with renal disease (group IV; OR, 7.38; 95% confidence interval, 0.858 -157.06) than in normal subjects (group I); however, this difference did not attain statistical significance.
Among the 48 patients with kidney disease (groups III and IV), only 2 were homozygous for ZϪ4 (data not shown). No diabetic patient with kidney disease (group III) was homozygous for the ZϪ4 allele. However, 11% of diabetics without DN (group II) were homozygous for the ZϪ4 allele (P ϭ NS). Among nondiabetics, the prevalence of the ZϪ4 allele was similar in those with (12.5%) and without kidney disease (15.0%; P ϭ NS). HSR. We identified eight alleles ranging from ZϪ12 to Z ϩ2 (Tables 2B and 3B ). The prevalence of the ZϪ2 allele was higher in IDDM patients with DN (group III) than in those without DN (group II). In group III, 43% of patients were homozygous for ZϪ2, and 81% of patients had one copy or more of the ZϪ2 allele. In contrast, in group II only 4% of patients were homozygous for ZϪ2, and only 36% had one copy or more of the ZϪ2 allele. Diabetics who were homozygous for ZϪ2 had an increased risk for DN compared with those homozygous for other alleles (OR, 22.5; 95% confidence interval, 1.6 -314) and those in whom the ZϪ2 allele was absent (OR, 18; 95% confidence interval, 2-159). IDDM volunteers who had one copy or more of ZϪ2 had increased risk (OR, 7.5; 95% confidence interval, 1.9 -29.4) for DN compared with those without the ZϪ2 allele.
ALDR1 mRNA
The overall mean levels of ALDR1 mRNA in the UNMHSC (0.06 Ϯ 0.04) and HSR (0.04 Ϯ 0.03) studies were different (P Ͻ 0.05). The distributions of ALDR1 mRNA levels within the UNMHSC and HSR volunteers were approximately normal. Moreover, the relationships between the respective groups at each study site were similar.
In the UNMHSC study, ALDR1 mRNA levels were higher in diabetics with renal disease (group III) than in all other groups (P Ͻ 0.01; Table 4 ). In contrast, ALDR1 mRNA levels were lower in volunteers with nondiabetic renal disease than in any other group (P Ͻ 0.01). These data indicate that renal disease per se did not lead to up-regulation of ALDR1 gene expression. In the HSR study, ALDR1 mRNA levels were higher in group III than in group I (P Ͻ 0.01) and group II (P Ͻ 0.01; Table 4 ).
Relationship of ALDR1 mRNA levels to ZϪ2 allele
We studied the relationship of ALDR1 mRNA levels to ZϪ2 allele in diabetics and nondiabetics in both the UNMHSC and HSR studies (Table 4) . In both studies, diabetics with one or more copy of the ZϪ2 allele had higher ALDR1 mRNA levels than did diabetics without the ZϪ2 allele. In the UNMHSC study, diabetics who were homozygous for ZϪ2 had higher ALDR1 mRNA levels than did diabetics who had only a single copy of ZϪ2. In contrast, in the HSR study ALDR1 mRNA levels were similar in IDDM patients homozygous and heterozygous for the ZϪ2 allele (P ϭ NS). In nondiabetics in both the UNMHSC and HSR studies, there appeared to be no relationship between the ZϪ2 allele and the levels of ALDR1 mRNA expression. These results are consistent with the hypothesis that increased expression of the structural ALDR1 gene in subjects with the ZϪ2 microsatellite allele requires the presence of diabetes and/or hyperglycemia. This observation is in concert with previous reports that glucose plays an important role in the regulation of ALDR1 gene expression (35) .
Discussion
We previously demonstrated that ALDR1 mRNA levels are increased in PBMC obtained from patients with DN (28) . The present study confirms and extends that original observation in samples from two different populations by demonstrating that (A-C)n microsatellite polymorphisms of the ALDR1 locus may modulate expression of the ALDR1 gene and the risk for DN.
Results from the UNMHSC and HSR groups are reported separately because of differences in these two population samples. Overall, the ALDR1 mRNA levels were higher in participants from UNMHSC than in those from HSR. This may reflect differences in the composition of the study groups and/or the effect of storing and transporting HSR samples to UNMHSC for analysis. The ethnic composition of the UNMHSC population sample reflects the ethnic diversity of New Mexico, in contrast with the more homogeneous population sample studied at HSR. It is possible that population admixture may contribute to the observed differences in the frequency of ZϪ2 alleles in the four groups studied at UNMHSC. However, ad-hoc analysis revealed that there were no observed differences in the frequency of the ZϪ2 allele between Hispanics and Caucasians in the study population. The UNMHSC study population was older than the HSR population (P Ͻ 0.01). The duration of diabetes in group II was greater in the HSR (25.4 Ϯ 7.5 yr) than in the UNMHSC (17.8 Ϯ 10.4 yr) population (P Ͻ 0.01). The degree of glycemic control, reflected by HbA 1c levels, was similar in diabetics at UNMHSC and HSR (P ϭ NS). ALDR1 mRNA levels were significantly higher in groups I (P Ͻ 001) and III (P Ͻ 0.01) in the UNMHSC study than in the HSR study. However, the relationships of ALDR1 mRNA levels among the different groups were similar in both studies. The prevalence of ZϪ2 in groups I, II, and III, respectively, was similar in the UNMHSC and HSR studies.
Our study confirms the observation that the frequency of the ZϪ2 allele is increased in IDDM patients with DN. However, in contrast to the report by Hessom et al., the frequency of the Zϩ2 allele in our study was low in IDDM patients with and without DN. The protective effect of Zϩ2 observed by Hessom et al. could be due to the absence of ZϪ2, rather than to a specific protective effect of Zϩ2. Neither Ko et al. nor Hessom et al. described the relationship between different microsatellite polymorphisms and the level of ALDR1 gene expression (29, 30) .
The results of our study are consistent with the hypothesis that specific polymorphisms may modulate the level of ALDR1 gene expression and the risk for DN in patients with IDDM. The effect of microsatellite polymorphisms on ALDR1 gene expression appears to be different in diabetics than that in nondiabetics. Among diabetics, ALDR1 mRNA levels were higher in those with one copy or more of the ZϪ2 alleles compared with those lacking the ZϪ2 allele. In contrast, among nondiabetics, ALDR1 mRNA levels in subjects homozygous or heterozygous for ZϪ2 were similar to levels in those lacking the ZϪ2 allele. These results indicate that diabetes and/or hyperglycemia are required for the ZϪ2 allele to lead to up-regulation of the ALDR1 gene.
These observations are consistent with the hypothesis that the associations of specific polymorphisms of the ALDR1 locus with DN may be mediated by changes in ALDR1 gene expression. Our study did not identify the mechanism by which these microsatellite polymorphisms may regulate ALDR1 gene expression. However, as this microsatellite is located in the 5Ј-region of the gene, different populations may be associated with differential binding of transcription factors. The expression of other genes (constitutive nitric oxide synthase and the T cell receptor ␤-chain) near this locus may also be altered and may also modulate the risk for DN. The osmotic response element (36) located at this locus may also contribute to environmental-genetic interactions that predispose to DN.
The present study has the limitations inherent in a casecontrol study that is not family or population based. Nevertheless, we were able to demonstrate an association among polymorphisms of the ALDR1 locus, ALDR1 gene expression, and DN. Family-based studies designed to assess linkage of DN have produced conflicting results. Imperatore et al. conducted genome-wide scans in affected Pima Indian sibling pairs (7). Both two-point and multipoint analyses revealed evidence of linkage between DN and D7S1840. This marker corresponds to cytogenetic location 7q35, which contains the ALDR1 gene. In contrast, a sibling pair study in Caucasians with IDDM conducted by Moczulski et al. found no evidence to support a role for ALDR1 as a major locus for DN (37) . The genetics of DN may differ significantly between ethnic groups and also between IDDM and NIDDM patients. Additional family-based studies are needed to clarify the putative role of ALDR1 in the pathogenesis of DN.
In summary, the present study supports our hypothesis that the ZϪ2 allele may be associated with up-regulation of ALDR1 gene expression and may increase the risk for DN in IDDM patients. This suggests a potential interaction between ALDR1 polymorphisms genotype and hyperglycemia and Group I, Normal; group II, IDDM without DN; group III, IDDM with DN; group IV, nondiabetics with kidney disease. ALDR1 mRNA expressed as ALDR1/␤-actin mRNA molar ratio, mean (SD). ALDR1-mRNA levels with same letter were not statistically different from others in the same group (same raw score; P Ͻ 0.05).
diabetes. These findings are consistent with a role for ALDR1 in the pathogenesis of DN and identify a possible mechanistic relationship among ALDR1 genotype, hyperglycemia, and ALDR1 gene expression.
